Although we live in a time of great discoveries and medical advancements, psoriasis is still in the group of diseases for which there is no efficient cure. There are numerous topical and systemic therapies to relieve the symptoms, but most often come with an increased number of adverse drug reactions. Therefore, the aim of this thesis is to analyze suspected adverse reactions of the part of antipsoriatics belonging to the Anatomical Therapeutic Chemical (ATC) group D05. This refers to the reports received in the Agency for Medicinal Products and Medical Devices of Croatia (HALMED) in the period from 2015. to 2019. The data were analyzed with regard to: reported drugs, source of the report, age and sex of the patient, expectedness, seriousness, type, outcome and the distribution of the adverse effects according to the system organ class (SOC). There were 46 reports received during the mentioned period, representing 0.28% in the total number of the reports. Majority of the reports were received from physicians, for female patients and an age group 18 to 64 years. A total of 136 adverse reactions were reported. According to the mechanism of occurrence most of them belong to the type A adverse reactions. Most of them have been reported for the System organ class (SOC) Gastrointestinal disorders, then for SOC Skin and subcutaneous tissue disorders and SOC General disorders and administration site conditions. Most commonly reported adverse reactions were nausea, diarrhea, vomiting, redness, itching and erythema. The results obtained at the national level only confirm the data reported in European (EudraVigilance) and worldwide (VigiBase) base of adverse effects.